The average one-year price target for Century Therapeutics (NasdaqCM:IPSC) has been revised to $4.20 / share. This is an ...

Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic, a cell therapy platform provider that partners with therapeutic developers to ensure cell therapies can achieve their full potential, has ...

Century Therapeutics Inc. (NASDAQ:IPSC) is one of the best fast growing penny stocks to buy according to analysts. On January 20, Piper Sandler increased its price target for Century Therapeutics to ...

Evotec has reached a collaboration with Censo Biotechnologies, using the latter’s patient-derived induced pluripotent stem cells (iPSC) to expand its platform for drug discovery. Scientists get iPSCs ...

A multi-institutional group, including members of the Tau Consortium, unveiled a stem cell tool kit for scientists studying primary tauopathies. In the November 12 issue of Stem Cell Reports, ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...